The Translational Neuropharmacology Group has focused on pharmacological mechanisms underlying HIV-associated neurocognitive disorders and mental health issues, as well as the optimization and development of pharmacological interventions potentially used to treat these conditions.
Bing
Su, MD, PhD, HCLD
Adjunct
Professor, Center of Integrated Global Biomedical Sciences
Member,
Translational Neuropharmacology Group
Director,
Quater Diagnostic Laboratory
Dr. Su is currently a
Board Certified High-Complexity Clinical Laboratory Director (HCLD) and an
expert in clinical toxicology. Previously, Dr. Su was an Adjunct Professor of Cancer
Genetics at the Roswell Park Comprehensive Cancer Center and a Research Professor
in the Department of Epidemiology and Environmental Health at the University at
Buffalo, State University of New York. Dr. Su has authored more than 30 publications
including scientific journal articles and book chapters. His research interest
includes substance use disorders, molecular diagnostics, next generation
sequencing, and genetic/epigenetic biomarkers.
Education
PhD, Fudan University, Shanghai,
China
MD, Henan Medical University, Henan, China
Publications
1. Su
W, Li S, Chen X, Yin L, Ma P, Ma Y, Su B. GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer. Oncotarget. 2017;
8(3):4449-4459.
2. Zhang
T, Lv C, Li L, Chen S, Liu S, Wang C, Su B.
Circulating miR-126 is a potential biomarker to predict the onset of type 2
diabetes mellitus in susceptible individuals. Biochem Biophys Res Commun. 2015;463(1-2):60-3.
3. Xie
CW, Zhou Y, Liu SL, Fang ZY, Su B, Zhang W. Gabarapl1 mediates androgen-regulated autophagy in
prostate cancer. Tumour Biol. 2015; 36(11):8727-33.
4. Ren
X, Wu X, Sui G, Gong Z, Yawson E, Wu B, Lai G, Ruan X, Gao H, Zhou F, Su B, Olson JR, Tang X. Chronic
trimethyltin chloride exposure and the development of
kidney stones in rats. J Appl
Toxicol. 2014 Sep 16. doi: 10.1002/jat.3054.
5. Ko
HK, Guo LW, Su B, Gao L, Gelman IH. Suppression
of Chemotaxis by SSeCKS via Scaffolding of Phosphoinositol Phosphates and the Recruitment of the Cdc42
GEF, Frabin, to the Leading Edge. PLoS One. 2014 Oct 30;9(10):e111534.
6. Su
B, Gao L, Baranowski C, Gillard B, Wang J, Ransom R, Ko HK, Gelman IH. A
genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through
counteracting PI3K/AKT signal pathway in prostate cancer. PLoS One. 2014 Jul 1;9(7):e101411.
7. Zhang
T, Lv C, Li L, Chen S, Liu S, Wang C, Su B. Plasma
miR-126 is a potential biomarker for early prediction of type 2 diabetes
mellitus in susceptible individuals. Biomed Res Int.
2013; 2013:761617.
8. Su
B, Gillard B, Gao L, Eng
KH, Gelman IH. Src controls castration recurrence of CWR22 prostate cancer
xenografts. Cancer Med. 2013;
2(6):784-92.
9. Tang
LH, Zhang W, Su B, Yu B. Long Non-coding RNA HOTAIR is associated with
motility, invasion and metastatic potential of metastatic melanoma. Biomed Res
Int. 2013; 2013:251098.
10. Wu
JH, Liao X, Yu B, Su B. Dasatinib inhibits primary
melanoma cell proliferation through morphology dependent disruption of Src ERK signaling. ONCOLOGY LETTERS 2013; 5: 527-532.
11. Su
B, Gao L, Meng F, Guo LW, Rothschild J, Gelman IH. Adhesion-mediated
cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene. 2013;
32(16):2016-26.
12. Tang
H, Wu Z, Zhang J, Su B. Salivary lncRNA as a
potential marker for oral squamous cell carcinoma diagnosis. Mol Med Report. 2013; 7(3):761-6.
13. Ma
Y, Yu WD, Su B, Seshadri M, Luo W, Trump D, Johnson
C. Regulation of motility, invasion, and metastatic potential of squamous cell
carcinoma by 1α,25-dihydroxycholecalciferol. Cancer. 2013;
119(3):563-74.
14. Guo
LW, Gao L, Rothschild J, Su B, Gelman IH. Control of
protein kinase C activity, phorbol ester-induced
cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12. J Biol
Chem. 2011; 286(44):38356-66.
15. Su
B, Bu Y, Engelberg D, and Gelman
IH. SSECKS/GRAVIN/AKAP12
inhibits cancer cell invasiveness and chemotaxis by suppressing a
PKC-RAF/MEK/ERK pathway. J. Biol. Chem. 2010; 285(7):4578-86.
16. Su
B, Zheng Q, Vaughan M, Bu Y, and Gelman IH. SSeCKS
metastasis-suppressing activity correlates with angiogenesis inhibition. Cancer
Res 2006; 66(11):5599-607.